Hostname: page-component-74656f9884-rdgjk Total loading time: 0 Render date: 2026-11-06T22:54:01.993Z Has data issue: false hasContentIssue false

Resistance mechanisms to mitochondrial electron transport inhibitors in a field-collected strain of Tetranychus urticae Koch (Acari: Tetranychidae)

Published online by Cambridge University Press:  01 July 2008

S. Van Pottelberge
Affiliation:
Laboratory of Agrozoology, Department of Crop Protection, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium
T. Van Leeuwen*
Affiliation:
Laboratory of Agrozoology, Department of Crop Protection, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium
R. Nauen
Affiliation:
Bayer CropScience AG, Research Insecticides, Insect Toxicology and Resistance, Geb. 6220, Alfred-Nobel-Str., 40789 Monheim, Germany
L. Tirry
Affiliation:
Laboratory of Agrozoology, Department of Crop Protection, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium
*
*Author for correspondence Fax: +32 (0)9 264 62 39 E-mail: thomas.vanleeuwen@ugent.be
Rights & Permissions [Opens in a new window]

Abstract

A Belgian field strain (MR-VP) of Tetranychus urticae (Koch) (Acari: Tetranychidae) exhibits different levels of resistance to four frequently used METI (mitochondrial electron transport inhibitor)-acaricides, i.e. tebufenpyrad, fenpyroximate, pyridaben and fenazaquin. Resistance factors for these compounds were 184, 1547, 5971 and 35, respectively. A 23.5-fold increase in 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity suggested that metabolic resistance through elevated levels of cytochrome P450 dependent monooxygenase-activity is a possible resistance mechanism.

However, synergism studies with different metabolic inhibitors revealed some contrasting resistance mechanisms between the METI-acaricides. Tebufenpyrad resistance could only be synergized after pre-treatment with the monooxygenase inhibitor piperonyl butoxide (PBO), whereas pyridaben resistance was strongly synergized both by PBO and the esterase inhibitor S,S,S-tributylphosphorotrithioate (DEF). Resistance levels to fenpyroximate could neither be suppressed by PBO nor by DEF. Although METI-acaricides are structurally related, these findings probably reflect a different role of esterases and mono-oxygenases in metabolic detoxification between these compounds. The overall lack of synergism by diethylmaleate (DEM) suggests that glutathione-S-transferases are not an important factor in resistance to METIs.

Reciprocal crosses between susceptible females and resistant males showed no maternal effect, and resistance to METI-acaricides was inherited generally as a dominant trait. Backcrosses with F1 females revealed striking differences in the mode of inheritance. Although resistance to fenpyroximate and pyridaben was under monogenic control, resistance to tebufenpyrad was under control of more than one gene.

Information

Type
Research Paper
Copyright
Copyright © 2008 Cambridge University Press
Figure 0

Table 1. Toxicity of tebufenpyrad, fenpyroximate and pyridaben with and without synergists to female adults of strains GSS and MR-VP.

Figure 1

Table 2. Probit statistics for the crosses (F1) tested against tebufenpyrad, fenpyroximate and pyridaben.

Figure 2

Fig. 1. Concentration-mortality curves for tebufenpyrad in MR-VP, GSS, the reciprocal crosses, the (GSS×MR-VP) F1♀×GSS♂ backcross (■) and the theoretical backcross on the basis of monogenic inheritance (□).

Figure 3

Fig. 2. Concentration-mortality curves for fenpyroximate in MR-VP, GSS, the reciprocal crosses, the (GSS×MR-VP) F1♀×GSS♂ backcross (■) and the theoretical backcross on the basis of monogenic inheritance (□).

Figure 4

Fig. 3. Concentration-mortality curves for pyridaben in MR-VP, GSS, the reciprocal crosses, the (GSS×MR-VP) F1♀×GSS♂ backcross (■) and the theoretical backcross on the basis of monogenic inheritance (□).

Figure 5

Fig. 4. 7-EFC O-deethylation activity of the GSS and MR-VP strain, their reciprocal crosses and MR-VP after 24 h pre-treatment with PBO (5000 mg l−1). Data are mean values±SEM (n=3). Different letters indicate significant differences (Tukey-test, p<0.05).

Figure 6

Table 3. Detoxifying enzyme activities in the GSS and MR-VP strain